Mahali, Sidhartha
Martinez, Rita
King, Melvin
Verbeck, Anthony
Harari, Oscar http://orcid.org/0000-0002-2635-6975
Benitez, Bruno A.
Horie, Kanta http://orcid.org/0000-0001-7736-2614
Sato, Chihiro
Temple, Sally
Karch, Celeste M. http://orcid.org/0000-0002-6854-5547
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 AG056293, R56 NS110890, RF1 AG053303)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 9 November 2021
Revised: 24 November 2022
Accepted: 29 November 2022
First Online: 10 December 2022
Competing interests
: ST is president of StemCultures, scientific co-founder of Luxa Biotech, and has served on the scientific advisory boards of Sana Biotechnology and Blue Rock Therapeutics and as a consultant to Merck. KH is an Eisai-sponsored visiting researcher at Washington University and has received salary from Eisai. The remaining authors declare no competing interests.
: The Washington University School of Medicine Institutional Review Board reviewed the protocol of the Knight Alzheimer Disease Research Center (ADRC) Neuropathology Core, from which clinically and neuropathologically well-characterized brain tissues were obtained. As tissue was obtained postmortem it was exempt from IRB approval. Research participants provided autopsy consent limited to removal of the brain. All data were analyzed anonymously. Skin biopsies were performed following written informed consent from the donor. The informed consent was approved by the Washington University School of Medicine Institutional Review Board and Ethics Committee (IRB 201104178 and 201306108).